Replies to post #169582 on Biotech Values

[bladerunner1717]

You are asking people to predict future based on incomplete information - even after Imetelstat data presentation at ASH it would still be incomplete information - even people with same or similar background would predict differently because everyone has to use some other information in the background to make this prediction, and that background information are different no matter what they do.

I'm not sure what your point is. How is this any different from any other biotech investment?

Look, jq1234, let's cut to the chase. You and Clark and PGS are implying to some degree or other that Dr. Tefferi is fudging a bit on the data. Hey, maybe you guys are right. For me and "nuere" and probably some others, we find it hard to believe that the doctor who wrote the standards for determining trial results in MF would now deliberately undermine those standards for personal reasons by misguiding folks in an ASH abstract. Let's wait and see what he has to present at ASH.

BTW, a very, very knowledgeable biotech investor who is long GERN wrote me today to remind me that the same kind of nit-picking of data (and trashing of PCYC management, which, as I recall was justly deserved) with Ibrutinib happened when PCYC was $12/share. (And, no, I'm not saying that Imetelstat is another Ibrutinib.) Time and the Market will tell.


Bladerunner